239101-33-8|Deferitrin|4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazol-4-(S)-carboxylic acid|-范德生物科技公司

Deferitrin

NMR下载 COA and HPLC MSDS下载
names：
4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazol-4-(S)-carboxylic acid
CAS号：
239101-33-8
MDL Number：
MF(分子式)： C11H11NO4S MW(分子量)： 253.27
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Deferitrin
英文别名	GT-56-252; GT 56 252; GT-56252; GT 56252; Deferitrin.
CAS号	239101-33-8
SMILES	O=C([C@]1(C)N=C(C2=CC=C(O)C=C2O)SC1)O
Inchi	InChI=1S/C11H11NO4S/c1-11(10(15)16)5-17-9(12-11)7-3-2-6(13)4-8(7)14/h2-4,13-14H,5H2,1H3,(H,15,16)/t11-/m1/s1
InchiKey	OEUUFNIKLCFNLN-LLVKDONJSA-N
分子式 Formula	C11H11NO4S
分子量 Molecular Weight	253.27
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Deferitrin(CAS:239101-33-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Deferitrin, also known as GT-56252, is an iron chelator potentially for the treatment of thelassemia and iron overload.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y. PubMed PMID: 21103911; PubMed Central PMCID: PMC3329216.

[2]Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem. 2008 Jul 10;51(13):3913-23. doi: 10.1021/jm800154m. PubMed PMID: 18533709; PubMed Central PMCID: PMC2759697.

[3] Barton JC. Drug evaluation: Deferitrin for iron overload disorders. IDrugs. 2007 Jul;10(7):480-90. PubMed PMID: 17642018.

[4] Barton JC. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders. IDrugs. 2007 Apr;10(4):270-81. Review. PubMed PMID: 17390251.

[5] Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006;30(2):329-47. Review. PubMed PMID: 16798657.

6: Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR. (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity. J Med Chem. 2006 May 4;49(9):2772-83. PubMed PMID: 16640338; PubMed Central PMCID: PMC2547084.7: Kontoghiorghes GJ. New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerg Drugs. 2006 Mar;11(1):1-5. PubMed PMID: 16503822.8: Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005 Dec;57(4):547-83. Review. PubMed PMID: 16382108.9: Donovan JM, Plone M, Dagher R, Bree M, Marquis J. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005;105

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开